Cue Biopharma Newsroom

Cue Biopharma's Promising Future: A Comprehensive Buy Rating Justification

TipRanksMay 16 00:30 ET

Oppenheimer Reaffirms Their Buy Rating on Cue Biopharma (CUE)

TipRanksMay 10 08:00 ET

Cue Biopharma Analyst Ratings

BenzingaApr 9 08:22 ET

Oppenheimer Maintains Outperform on Cue Biopharma, Maintains $10 Price Target

BenzingaApr 9 08:22 ET

Oppenheimer Remains a Buy on Cue Biopharma (CUE)

TipRanksApr 9 07:50 ET

Cue Biopharma (CUE) Gets a Buy From Stifel Nicolaus

TipRanksApr 9 07:10 ET

Cue Biopharma Analyst Ratings

BenzingaApr 3 12:06 ET

Piper Sandler Remains a Buy on Cue Biopharma (CUE)

TipRanksApr 3 07:11 ET

Cue Biopharma Analyst Ratings

BenzingaMar 13 09:04 ET

Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Intellia Therapeutics (NTLA) and Cue Biopharma (CUE)

TipRanksFeb 26 08:10 ET

Cue Biopharma (CUE) Gets a Buy From Piper Sandler

TipRanksFeb 20 07:45 ET

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Cue Biopharma (CUE)

TipRanksNov 13, 2023 14:10 ET

Analysts Conflicted on These Healthcare Names: Cue Biopharma (CUE) and Mirati Therapeutics (MRTX)

TipRanksNov 7, 2023 00:41 ET

Piper Sandler Maintains Overweight on Cue Biopharma, Raises Price Target to $8

BenzingaNov 6, 2023 10:40 ET

Cue Biopharma Analyst Ratings

BenzingaNov 6, 2023 10:40 ET

Analysts Offer Insights on Healthcare Companies: Cue Biopharma (CUE), Zoetis (ZTS) and CymaBay Therapeutics (CBAY)

TipRanksNov 6, 2023 07:51 ET

Cue Biopharma (CUE) Gets a Buy From Piper Sandler

TipRanksAug 10, 2023 09:16 ET

JMP Securities Keeps Their Buy Rating on Cue Biopharma (CUE)

TipRanksAug 10, 2023 00:15 ET

Oppenheimer Assumes Cue Biopharma at Outperform, Announces Price Target of $10

BenzingaJun 26, 2023 06:50 ET

Analysts Conflicted on These Healthcare Names: Cue Biopharma (CUE) and Corvus Pharmaceuticals (CRVS)

TipRanksJun 15, 2023 09:30 ET